REGENXBIO, Inc. (RGNX)
8.94
-0.26
(-2.83%)
USD |
NASDAQ |
Sep 04, 16:00
8.925
-0.02
(-0.17%)
After-Hours: 20:00
REGENXBIO SG&A Expense (TTM) : 85.56M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 85.56M |
| March 31, 2026 | 83.82M |
| December 31, 2025 | 82.86M |
| September 30, 2025 | 80.53M |
| June 30, 2025 | 79.70M |
| March 31, 2025 | 78.68M |
| December 31, 2024 | 76.62M |
| September 30, 2024 | 75.65M |
| June 30, 2024 | 79.31M |
| March 31, 2024 | 84.15M |
| December 31, 2023 | 88.49M |
| September 30, 2023 | 90.62M |
| June 30, 2023 | 88.46M |
| March 31, 2023 | 85.60M |
| December 31, 2022 | 85.28M |
| September 30, 2022 | 86.11M |
| June 30, 2022 | 86.22M |
| March 31, 2022 | 83.81M |
| December 31, 2021 | 79.33M |
| September 30, 2021 | 74.86M |
| June 30, 2021 | 69.69M |
| March 31, 2021 | 66.82M |
| December 31, 2020 | 63.82M |
| September 30, 2020 | 60.70M |
| Date | Value |
|---|---|
| June 30, 2020 | 57.24M |
| March 31, 2020 | 55.09M |
| December 31, 2019 | 51.82M |
| September 30, 2019 | 48.51M |
| June 30, 2019 | 45.12M |
| March 31, 2019 | 40.03M |
| December 31, 2018 | 36.85M |
| September 30, 2018 | 30.51M |
| June 30, 2018 | 30.95M |
| March 31, 2018 | 28.99M |
| December 31, 2017 | 27.23M |
| September 30, 2017 | 28.16M |
| June 30, 2017 | 24.92M |
| March 31, 2017 | 24.73M |
| December 31, 2016 | 23.59M |
| September 30, 2016 | 22.08M |
| June 30, 2016 | 18.45M |
| March 31, 2016 | 15.68M |
| December 31, 2015 | 11.91M |
| September 30, 2015 | 8.314M |
| June 30, 2015 | 5.747M |
| March 31, 2015 | 2.35M |
| March 31, 2014 | 0.634M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| AbbVie, Inc. | 14.67B |
| Capricor Therapeutics, Inc. | 35.43M |
| United Therapeutics Corp. | 644.60M |
| Ardelyx, Inc. | 373.73M |
| Biomea Fusion, Inc. | 15.08M |